Acutus Medical Expands Leadership Team with Key Hires to Advance Technology and Continue Growth in Global Electrophysiology (EP) Market

SAN DIEGO, CA., September 22, 2015 — Acutus Medical, Inc., an innovative medical device company dedicated to redefining the electrophysiologist (EP) market, today announced the appointment of three new executive team members. John Dahldorf, Martin Chambers and Steven McQuillan join the company as Chief Financial Officer, Chief Commercial Officer and Senior Vice President, Regulatory and Clinical Affairs, respectively.

"John, Martin and Steven come to us with the technical and commercial experience necessary to transform Acutus Medical from an early stage start-up company to a full commercial entity," said Randy Werneth, President and Chief Executive Officer of Acutus Medical. "With their leadership and knowledge and our existing bench strength, we are confident that Acutus Medical will revolutionize the EP market and realize the full potential of our broad portfolio of products, including the AcQMap™ High Resolution, Imaging and Mapping System."

Mr. Dahldorf has more than 30 years of financial, operational and leadership experience in the healthcare industry. He brings comprehensive knowledge of acquisitions and initial public offerings, as well as development and execution of strategic plans to the company. Mr. Dahldorf joins Acutus Medical from Volcano Corporation (formerly Volcano Therapeutics Inc.), where he held positions as the Chief Finance Officer, Principal Accounting Officer, General Manager and Secretary since 2003. Mr. Dahldorf also served in executive roles at Digirad Corporation, Arrow Electronics, Inc., and Baxter Healthcare. Mr. Dahldorf received Bachelor of Finance and Master of Business Administration degrees, both from Western Illinois University.

Mr. Chambers joins Acutus Medical with more than 30 years of sales and marketing experience, focused primarily on the global commercialization of implantable cardiac devices and peripheral/cardiac vascular interventional devices. Mr. Chambers has held a number of executive sales and marketing positions throughout his career with leading medical device companies including Guidant Corporation, EV3, Inc. (acquired by Covidien PLC), Medtronic, Ablation Frontiers, Inc. (acquired by Medtronic) and, most recently, Spinal Modulation, Inc. (acquired by St. Jude Medical). Mr. Chambers received his degree in International Marketing from Southampton University, U.K.

Mr. McQuillan brings over 25 years of experience in clinical trial design and execution, as well as a deep understanding of the global medical device regulatory environment. Prior to joining Acutus Medical, Mr. McQuillan served as Senior Vice President of Clinical and Regulatory Affairs at Spinal Modulation, Inc. (acquired by St. Jude Medical), and has held several key leadership positions at the University of Minnesota, Department of Surgery, CPI/Guidant, Boston Scientific Corporation and Medtronic (Atrial Fibrillation Solutions). Mr. McQuillan received Engineering Statistics and Biostatistics degrees from the University of Minnesota.

About Acutus Medical
Acutus Medical is a privately held medical device company developing a minimally invasive cardiac imaging and mapping system and catheters that have the potential to redefine clinical practice and improve patient outcomes in irregular and complex heart rhythm disorders. The company is currently pursuing CE mark approval in Europe for the full suite of AcQMap™ System products. Acutus Medical is located in San Diego, CA. To learn more, visit www.acutusmedical.com.

Forward Looking Statements
This document includes forward-looking statements regarding Acutus Medical's Cardiac Imaging and Mapping Technology System. Any statement describing Acutus Medical's goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical. As a result, you are cautioned not to rely on these forward-looking statements.

Media Contact:
Susan Heins at Pure Communications
Email: [email protected]
Phone: 864.286.9597

Best regards,
Susan Heins
864.286.9597 (Office)
864.346.8336 (Cell)

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.